ストックスクリーナーアプリを入手
0.8501
0.44%
-0.0124
前日終値:
$0.8625
開ける：
$0.89
24時間の取引高:
13,613
Relative Volume:
0.09
時価総額：
$84.32M
収益：
-
当期純損益:
$-30.15M
株価収益率:
-0.9342
EPS:
-0.91
ネットキャッシュフロー:
$-31.63M
1週間 パフォーマンス:
-8.65%
1か月 パフォーマンス:
+26.09%
6か月 パフォーマンス:
-62.17%
1年 パフォーマンス:
-50.93%
1日の値動き範囲:
$0.8351
$0.89
1週間の範囲:
$0.80
$0.99
52週間の値動き範囲:
$0.55
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
名前
Context Therapeutics Inc
セクター
電話
267-225-7416
住所
2001 MARKET STREET, PHILADELPHIA
CNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.8585 | 84.32M | 0 | -30.15M | -31.63M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.87 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.30 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
650.51 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.20 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.53 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2025-01-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-11-25 | 開始されました | D. Boral Capital | Buy |
| 2024-05-16 | 開始されました | Piper Sandler | Overweight |
Context Therapeutics Inc (CNTX) 最新ニュース
What is William Blair’s Estimate for CNTX Q2 Earnings? - Defense World
Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Geode Capital Management LLC - Defense World
Context Therapeutics’ (CNTX) Outperform Rating Reiterated at William Blair - Defense World
Context Therapeutics’ (CNTX) Buy Rating Reiterated at D. Boral Capital - Defense World
Q1 Earnings Forecast for CNTX Issued By William Blair - Defense World
Context Therapeutics reports progress in cancer treatment By Investing.com - Investing.com India
Context Therapeutics (CNTX) Presents Promising Data on CT-95 at AACR 2025 | CNTX Stock News - GuruFocus
Context Therapeutics Presents Preclinical and Translational - GlobeNewswire
Breakthrough Cancer Treatment CT-95 Reveals Unique Binding Mechanism in Multiple Tumor Types - Stock Titan
Q1 Earnings Estimate for CNTX Issued By William Blair - Defense World
Context Therapeutics (NASDAQ:CNTX) Coverage Initiated by Analysts at William Blair - Defense World
William Blair Initiates Coverage of Context Therapeutics (CNTX) with Outperform Recommendation - Nasdaq
Bet on These 5 Top-Ranked Stocks With Rising P/E - NewsBreak: Local News & Alerts
William Blair starts Context Therapeutics stock with Outperform By Investing.com - Investing.com Canada
Stocks in play: Parkland Corporation - The Globe and Mail
Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results - ADVFN
Context Therapeutics Reports Full Year 2024 Operating and Financial Results - ADVFN
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts - Defense World
Context Therapeutics Begins Phase 1 Trial of CT-95 Targeting Mesothelin-Expressing Cancers - MSN
D. Boral Capital Reaffirms Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN
Context Swoons on CT-95 First Dose - Baystreet.ca
Context Therapeutics Begins Phase 1 Trial for CT-95 - TipRanks
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95 - GlobeNewswire
Breakthrough Cancer Treatment Launches Trial: Targets 30% of All Cancer Types - Stock Titan
Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance
Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance
Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo
Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo
Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan
Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks
Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView
Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan
JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK
What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World
HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World
Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance
Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN
Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail
Context Therapeutics Inc. (CNTX) reports earnings - Quartz
Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline - StockTitan
Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025 - Nasdaq
Context Therapeutics Inc. SEC 10-K Report - TradingView
CONTEXT THERAPEUTICS Earnings Preview: Recent $CNTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure - Business Wire
Context Therapeutics Inc (CNTX) 財務データ
収益
当期純利益
現金流量
EPS
0.01%
2.96%
大文字化:
|
ボリューム (24 時間):